Fig. 2

Follistatin (FST) treatment inhibits migration, and elevated FST expression is correlated with better breast cancer outcomes. Modified Boyden chamber migration assays of (a) MCF10A and (b) 4T1 cells treated with vehicle (Veh), 100 ng/ml recombinant human (rh) activin A (Act), or activin A plus rhFST (400 ng/ml). Migrated cells were quantified in five independent fields per filter and normalized to vehicle (*p < 0.05 compared with vehicle, ^† p < 0.05 compared with activin). c Kaplan-Meier analysis of recurrence-free survival of patients with breast cancer with tumors stratified by FST expression using a 3554-patient cohort representing all breast cancer subtypes (FST low, n = 967; FST high, n = 2587). d Kaplan-Meier analysis of the prognostic significance of FST expression on breast cancer metastasis to the brain/lung in the Bos et al. [24] cohort (FST low, n = 149; FST high, n = 17)